TMDI - Titan Medical surges 13% as Oppenheimer initiates with a buy

Oppenheimer analyst Suraj Kalia has initiated shares of Titan Medical (TMDI) with a buy rating and a $4 price target.Given yesterday's closing price, that represents upside of ~123%.Kalia calls the Titan an "emerging player in the robotic surgery space," and says the company's Enos system the only single-port robotic surgery platform besides Intuitive Surgical's da Vinci.Kalia adds that the company's 2020 licensing agreement with Medtronic is central to his bullish call.Titan shares are up 13.4% to $2.03.

For further details see:

Titan Medical surges 13% as Oppenheimer initiates with a buy